Phase II registrational trial of onapristone in patients with recurrent or metastatic endometrial cancer.
Phase of Trial: Phase II
Latest Information Update: 16 May 2016
At a glance
- Drugs Onapristone (Primary)
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- Sponsors Arno Therapeutics
- 16 May 2016 According to Arno Therapeutics media release, company closed this study. But the decision was not based on any safety or lack of efficacy signal and the Company will continue to provide onapristone to all patients currently enrolled in this trial on a compassionate use basis.
- 16 May 2016 Status changed from recruiting to discontinued, as per Arno Therapeutics media release.
- 30 Mar 2016 According to an Arno Therapeutics media release, status changed from planning to recruiting.